ASRT
Assertio Holdings, Inc. NASDAQ$22.16
Mkt Cap $142.8M
52w Low $8.61
99.0% of range
52w High $22.30
50d MA $15.83
200d MA $12.73
P/E (TTM)
-3.9x
EV/EBITDA
6.8x
P/B
1.3x
Debt/Equity
0.4x
ROE
-32.3%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$15.83
200d MA
$12.73
Avg Volume
141.6K
About
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoul…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -3.05 | -1.86 | +39.0% | 11.77 | +2.7% | +6.2% | +16.2% | +16.6% | +13.6% | +18.9% | — |
| Nov 10, 2025 | AMC | -1.20 | 1.65 | +237.5% | 12.02 | -1.7% | +14.8% | +7.9% | +2.9% | -1.2% | -6.4% | — |
| Aug 11, 2025 | AMC | -0.10 | -0.17 | -70.0% | 10.88 | +3.4% | +13.8% | +11.9% | +12.8% | +12.1% | +11.8% | — |
| May 12, 2025 | AMC | -0.06 | -0.14 | -133.3% | 9.23 | -1.0% | -1.1% | -0.5% | +3.9% | +8.2% | +15.5% | — |
| Mar 12, 2025 | AMC | -0.05 | -0.11 | -120.0% | 11.68 | -3.7% | -7.4% | -7.3% | -6.3% | -7.8% | -8.8% | — |
| Nov 11, 2024 | AMC | -0.05 | -0.03 | +40.0% | 13.88 | +1.1% | -7.9% | -7.3% | -9.0% | -12.3% | -9.0% | — |
| Aug 7, 2024 | AMC | -0.03 | -0.04 | -25.0% | 18.45 | +1.6% | -11.4% | -10.6% | -13.0% | -9.8% | -13.0% | — |
| May 6, 2024 | AMC | 0.12 | 0.04 | -66.7% | 18.30 | -3.3% | -9.0% | -13.1% | -13.9% | -21.3% | -13.9% | — |
| Mar 11, 2024 | AMC | -0.00 | 0.11 | +2950.8% | 14.02 | +7.0% | +8.1% | +22.0% | +16.6% | +19.8% | +11.3% | — |
| Nov 8, 2023 | AMC | 0.14 | 0.01 | -92.9% | 31.95 | -45.5% | -43.2% | -47.4% | -51.2% | -49.8% | -46.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Lake Street | Downgrade | Buy → Hold | — | $18.41 | $18.05 | -2.0% | -2.1% | -2.1% | -2.1% | -2.1% | -2.1% |
| Apr 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $18.41 | $18.05 | -2.0% | -2.1% | -2.1% | -2.1% | -2.1% | -2.1% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.14 | $9.26 | +1.3% | +5.4% | +4.3% | +3.2% | +1.9% | +0.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.88 | $11.25 | +3.4% | +13.8% | +11.9% | +12.8% | +12.1% | +11.8% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.99 | $10.05 | +0.6% | +6.7% | +3.0% | +3.0% | +6.6% | +5.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.77 | $10.95 | +1.7% | -1.1% | -0.9% | +0.7% | +5.4% | +7.0% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $13.95 | +1.1% | +2.2% | +0.6% | -5.8% | -8.3% | -3.7% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.15 | +0.3% | +7.4% | +4.1% | +3.9% | +6.3% | +8.4% |
| Mar 12 | Lake Street | Maintains | Buy → Buy | — | $14.02 | $15.00 | +7.0% | +8.1% | +22.0% | +16.6% | +19.8% | +11.3% |
| Nov 3 | BWS Financial | Maintains | Buy → Buy | — | $31.95 | $32.85 | +2.8% | +9.9% | +3.8% | +4.2% | +0.0% | -43.2% |
Recent Filings
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Assertio Holdings disclosed material non-public information via press release filing, though the specific disclosure content requires reviewing the attached exhibit for investor impact assessment.
May 5
8-K · 1.01
!!! Very High
Assertio Holdings, Inc. -- 8-K 1.01: Merger Agreement
Assertio Holdings agreed to merge with Garda Therapeutics under an amended merger agreement, potentially consolidating the two pharmaceutical companies and reshaping Assertio's corporate structure.
May 4
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Assertio Holdings disclosed material information through a press release filing, though the specific details aren't provided in this summary, so investors should review Exhibit 99.1 for the announcement's impact on ASRT.
Apr 29
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Garda plans to launch a tender offer for all outstanding Assertio Holdings shares on April 29, 2026, following completion of the required regulatory review period under their merger agreement.
Apr 21
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Assertio divested its core therapeutic business to a litigation-focused acquirer, potentially signaling a pivot toward legacy litigation monetization rather than drug development, which fundamentally changes the company's business model and risk profile.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
ASRT's CEO agreed to amended restrictive covenants tied to the merger, likely signaling management continuity post-acquisition but potentially restricting his future employment opportunities and warranting investor scrutiny of deal terms.
Apr 9
8-K · 1.01
!!! Very High
Unknown — 8-K 1.01: Merger Agreement
ASRT likely faces significant dilution or loss of independence as it pursues a merger with Garda Therapeutics, requiring investors to reassess their position based on deal terms and valuation.
Apr 9
8-K
Unknown — 8-K Filing
Assertio beat FY2025 guidance and projects modest 2026 growth ($110-125M sales), signaling operational stability but limited expansion—investors should assess whether the narrow guidance range reflects confidence or maturing market headwinds.
Mar 16
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics appointed a new CFO with significant biotech finance experience, including prior roles at Jaguar Gene Therapy and board positions at Tectonic Therapeutic, strengthening leadership capabilities.
Feb 13
Data updated apr 24, 2026 7:19pm
· Source: massive.com